Bonsang-Kitzis Hélène, Panchbhaya Nabilah, Bats Anne-Sophie, Pujade-Lauraine Eric, Pautier Patricia, Ngô Charlotte, Le Frère-Belda Marie-Aude, Kalbacher Elsa, Floquet Anne, Berton-Rigaud Dominique, Lefeuvre-Plesse Claudia, Fabbro Michel, Ray-Coquard Isabelle, Lécuru Fabrice
Gynecological and Breast Surgery and Cancerology Center, RAMSAY-Générale de Santé, Hôpital Privé des Peupliers, 75013 Paris, France.
GINECO/TMRG Network, 75008 Paris, France.
Cancers (Basel). 2022 May 9;14(9):2345. doi: 10.3390/cancers14092345.
The surgical specificities of advanced low-grade serous ovarian carcinoma (LGSOC) have been little investigated. Our objective was to describe surgical procedures/complications in primary (PDS) compared to interval debulking surgery (neoadjuvant chemotherapy and interval debulking surgery, NACT-IDS) and to assess the survival (progression-free (PFS) and overall survival (OS)) in patients with advanced LGSOC. We retrospectively analyzed advanced LGSOC from a nationwide registry (January 2000 to July 2017). A total of 127 patients were included (48% PDS and 35% NACT-IDS). Peritoneal carcinomatosis was more severe ( = 0.01 to 0.0001, according to sites), surgery more complex ( = 0.03) and late postoperative morbidity more frequent ( = 0.03) and more severe in the NACT-IDS group. PFS and OS were similar in patients with CC0 and CC1 residual disease after PDS or IDS. Prognosis was poorest for NACT-IDS patients with CC2/CC3 resection (PFS: HR = 2.31, IC95% (1.3-4.58); = 0.005; OS: HR = 4.98, IC95% (1.59-15.61); = 0.006). NACT has no benefit in terms of surgical outputs in patients with advanced LGSOC. Patients with complete resection or minimal residual disease (CC0 and CC1) have similar prognoses. On the other hand, patients with CC2 and more residual disease have similar survival rates compared to nonoperated patients. Primary cytoreduction with complete or with minimal residuals should be preferred when feasible.
晚期低级别浆液性卵巢癌(LGSOC)的手术特异性鲜有研究。我们的目标是描述与间歇性肿瘤细胞减灭术(新辅助化疗和间歇性肿瘤细胞减灭术,NACT-IDS)相比,初次肿瘤细胞减灭术(PDS)的手术程序/并发症,并评估晚期LGSOC患者的生存率(无进展生存期(PFS)和总生存期(OS))。我们回顾性分析了来自全国登记处(2000年1月至2017年7月)的晚期LGSOC病例。共纳入127例患者(48%为PDS,35%为NACT-IDS)。NACT-IDS组的腹膜癌转移更严重(根据部位,P=0.01至0.0001),手术更复杂(P=0.03),术后晚期发病率更高(P=0.03)且更严重。PDS或IDS后CC0和CC1残留疾病患者的PFS和OS相似。CC2/CC3切除的NACT-IDS患者预后最差(PFS:HR=2.31,95%CI(1.3-4.58);P=0.005;OS:HR=4.98,95%CI(1.59-15.61);P=0.006)。对于晚期LGSOC患者,NACT在手术结果方面没有益处。完全切除或残留极少(CC0和CC1)的患者预后相似。另一方面,与未手术患者相比,残留CC2及以上疾病的患者生存率相似。可行时应首选完全或残留极少的初次细胞减灭术。